Stada Arz first-half 2012 sales rise 7%

8 August 2012

German generic and branded drugmaker Stada Arzneimittel (SAZ: GR) reported first-half 2012 financial results, showing that group sales grew 7% year-on-year to 885.2 million euros ($1.09 billion).

Adjusted EBITDA and adjusted earnings per share both rise to 176.7 million euros (+10%) and 1.19 euros (+7%), respectively. One-time special effects in the amount of 25.7 million euros before taxes primarily due to the planned continuation of the cost efficiency program “STADA – build the future”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Generics